Celleron Therapeutics appoints Bill Fleming as its Chief Financial Officer

with No Comments

Oxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer
medicines company, developing novel small molecule therapeutics, announced today the
appointment of Bill Fleming as its Chief Financial Officer. This appointment represents an
important milestone for the company which aims to benefit cancer patients through
developing new and improved medicines.

Bill’s career spans over 25 years in a broad range of finance positions in the biotech arena.
Holding a law degree from Cambridge University and as a qualified ACMA, Bill has
accumulated international FD/CFO experience in small venture-backed companies and large
blue chips.

Bill served as European Finance Director for Visible Genetics, a pioneering company in the
field of nucleic acid diagnostics, subsequently holding senior finance positions for Bayer
Healthcare in Europe and the USA. Bill played a leading role in securing investment for
Oxford University spinout Oxitec and in its successful acquisition by Intrexon Corporation.

“Celleron Therapeutics is at a significant stage in its growth, with clinical trials in a variety of
unmet cancer indications underway” said CEO Professor Nick La Thangue. We are delighted
that Bill will be joining us, where he can apply his considerable financial knowledge derived
from healthcare and life sciences to help progress the Company’s clinical and commercial

Bill Fleming commented “It is a great pleasure to join Celleron Therapeutics. The Company
has amassed a pipeline of innovative drugs in clinical trials. I look forward to applying my
extensive experience and knowledge in generating commercial traction and financial

About Celleron Therapeutics

Celleron Therapeutics, based on the Oxford Science Park, UK, is a precision cancer medicine
company focussed on developing a suite of novel drugs. It is a spin-out of Oxford University
and has secured a number of exclusive license agreements with pharmaceutical companies,
including Astra Zeneca. The Company has entered into a license with China-based Company
Nuance. Celleron’s precision medicine approach is supported by a companion diagnostic
biomarker platform, which allows new drugs to be tailored to responsive tumours. Celleron
has two Phase 2 clinical assets: CXD101 is a novel dual mechanism HDAC inhibitor which has
unique immuno-modulatory effects, and CXD201 represents a new type of topoisomerase